Agree 100%. JUstin is not giving big discounts either for financiers or new hires. He knows what he is doing and has a network that is exceptional. With the company's demonstrated consistent outsized growth rate, its ability to add new product lines w/i VeritasMD, its ease of raising growth capital and now the new Telemedicine focus Justin will be able to pick and choose new product licenses from small Pharma companies with great products and limited marketing ability. Price targets are ramping up IMO.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.